Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
The Journal of Infectious Diseases|December 7, 2016
Chikungunya Virus Vaccines: Viral Vector-Based ApproachesKatrin Ramsauer, Frédéric Tangy
Frontiers in Immunology|May 7, 2020
Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus InfectionsSabrina Schrauf, Roland Tschismarov, Erich Tauber, et al.
Expert Review of Vaccines|January 3, 2019
Measles-vectored vaccine approaches against viral infections: a focus on ChikungunyaChristiane Gerke, Phanramphoei N Frantz, Katrin Ramsauer, et al.
EMBO Reports|April 3, 2003
Phosphorylation of the Stat1 transactivating domain is required for the response to type I interferonsAndreas Pilz, Katrin Ramsauer, Hamid Heidari, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|May 21, 2026
A regional coalition for Lassa fever vaccine development and preparedness in West Africa: a practice-based PerspectiveAishat Bukola Usman, Oyeronke Oyebanji, Virgil Kuassi Lokossou, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2007
Distinct modes of action applied by transcription factors STAT1 and IRF1 to initiate transcription of the IFN-gamma-inducible gbp2 geneKatrin Ramsauer, Matthias Farlik, Gordin Zupkovitz, et al.
Immunity|December 13, 2003
Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunityLouisa Varinou, Katrin Ramsauer, Marina Karaghiosoff, et al.
Journal of Applied Toxicology : JAT|December 8, 2022
Biodistribution and toxicology evaluation of a recombinant measles Schwarz-based Lassa vaccine in cynomolgus macaquesSabrina Schrauf, Yvonne Tomberger, Sham Nambulli, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 17, 2002
p38 MAPK enhances STAT1-dependent transcription independently of Ser-727 phosphorylationKatrin Ramsauer, Iwona Sadzak, Almudena Porras, et al.
Lancet (London, England)|November 10, 2018
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trialEmil C Reisinger, Roland Tschismarov, Eckhard Beubler, et al.
Pageof 3